Gabriele Antonarelli

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients.

Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients.

Journal: JAMA network open

Published: May 04, 2026

Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study.

Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 15, 2026

Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study.

Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study.

Journal: ESMO open

Published: December 01, 2025

Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.

Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 25, 2025

Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer.

Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer.

Journal: ESMO open

Published: July 02, 2025

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 28, 2025

Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.

Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.

Journal: ESMO open

Published: February 28, 2025

Redefining clinical trial strategic design to support drug approval in medical oncology.

Redefining clinical trial strategic design to support drug approval in medical oncology.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 27, 2025

An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer.

An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer.

Journal: Expert opinion on pharmacotherapy

Published: January 23, 2025

From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials.

From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials.

Journal: Cancer treatment reviews

Published: January 22, 2025

Moving toward response-adapted trials in oncology.

Moving toward response-adapted trials in oncology.

Journal: Nature medicine

Published: November 11, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026